Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9542) 9542
Publication (800) 800
Newsletter (228) 228
Book Review (83) 83
Newspaper Article (38) 38
Book Chapter (26) 26
Conference Proceeding (10) 10
Magazine Article (9) 9
Dissertation (7) 7
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5305) 5305
dexamethasone (4677) 4677
male (3847) 3847
animals (3569) 3569
female (3339) 3339
index medicus (3263) 3263
dexamethasone - pharmacology (2955) 2955
middle aged (1962) 1962
adult (1872) 1872
dexamethasone - administration & dosage (1726) 1726
rats (1707) 1707
aged (1502) 1502
oncology (1279) 1279
dexamethasone - therapeutic use (1199) 1199
mice (1027) 1027
multiple myeloma - drug therapy (1019) 1019
treatment outcome (1017) 1017
hematology (996) 996
thalidomide - analogs & derivatives (971) 971
pharmacology & pharmacy (959) 959
multiple myeloma (924) 924
antineoplastic combined chemotherapy protocols - therapeutic use (914) 914
steroids (826) 826
dexamethasone - analogs & derivatives (794) 794
cells, cultured (742) 742
glucocorticoids - pharmacology (723) 723
endocrinology & metabolism (694) 694
care and treatment (689) 689
corticosteroids (683) 683
bortezomib (681) 681
dose-response relationship, drug (672) 672
glucocorticoids (668) 668
biochemistry & molecular biology (637) 637
chemotherapy (632) 632
analysis (609) 609
lenalidomide (606) 606
research (599) 599
time factors (597) 597
thalidomide - administration & dosage (596) 596
therapy (584) 584
expression (555) 555
aged, 80 and over (526) 526
cancer (521) 521
thalidomide (519) 519
surgery (507) 507
adolescent (505) 505
thalidomide - therapeutic use (501) 501
medicine & public health (491) 491
cell line (477) 477
double-blind method (462) 462
drug therapy, combination (455) 455
pain (450) 450
neurosciences (441) 441
dexamethasone - adverse effects (429) 429
cell biology (423) 423
prospective studies (416) 416
drug therapy (411) 411
cells (405) 405
antineoplastic combined chemotherapy protocols - adverse effects (399) 399
receptors, glucocorticoid - metabolism (393) 393
kinetics (392) 392
stem-cell transplantation (377) 377
rats, sprague-dawley (370) 370
clinical trials (365) 365
antineoplastic agents - therapeutic use (364) 364
inflammation (362) 362
immunology (357) 357
health aspects (353) 353
apoptosis (352) 352
dexamethasone - metabolism (347) 347
survival (345) 345
glucocorticoids - administration & dosage (340) 340
dosage and administration (329) 329
plus dexamethasone (323) 323
prevention (322) 322
thalidomide - adverse effects (321) 321
article (318) 318
recurrence (315) 315
multiple myeloma - pathology (314) 314
pregnancy (312) 312
in-vitro (307) 307
nausea (307) 307
rats, wistar (307) 307
anti-inflammatory agents - pharmacology (305) 305
abridged index medicus (300) 300
central nervous system depressants (299) 299
hydrocortisone - blood (296) 296
rats, inbred strains (293) 293
prednisolone - analogs & derivatives (290) 290
anti-inflammatory agents - therapeutic use (289) 289
young adult (285) 285
efficacy (283) 283
double-blind (280) 280
in vitro techniques (278) 278
activation (277) 277
glucocorticoids - therapeutic use (277) 277
anti-inflammatory agents - administration & dosage (276) 276
child (266) 266
rna, messenger - metabolism (266) 266
gene-expression (265) 265
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9273) 9273
French (115) 115
German (105) 105
Japanese (81) 81
Italian (53) 53
Spanish (50) 50
Chinese (49) 49
Russian (31) 31
Polish (24) 24
Czech (10) 10
Dutch (7) 7
Korean (6) 6
Portuguese (6) 6
Persian (5) 5
Hungarian (4) 4
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Arabic (1) 1
Hebrew (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


41. Full Text Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
by Dimopoulos, Meletios A and Kiamouris, Christos and Gika, Dimitra and Deliveliotis, Charalambos and Giannopoulos, Aris and Zervas, Anastasios and Alamanis, Christos and Constantinidis, Constantinos and Koutsilieris, Michael
Urology, ISSN 0090-4295, 2004, Volume 63, Issue 1, pp. 120 - 125
Objectives. To evaluate prospectively the combination of a luteinizing hormone-releasing hormone analog with a somatostatin analog and dexamethasone in... 
ETOPOSIDE | THERAPY | ORAL ESTRAMUSTINE | CLINICAL-TRIALS | DISEASE | UROLOGY & NEPHROLOGY | CASTRATION | CARCINOMA | CELL-DEATH | Somatostatin - adverse effects | Estramustine - administration & dosage | Humans | Middle Aged | Somatostatin - administration & dosage | Bone Neoplasms - secondary | Dexamethasone - adverse effects | Male | Triptorelin Pamoate - administration & dosage | Life Tables | Peptides, Cyclic - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aged, 80 and over | Bone Neoplasms - drug therapy | Gonadotropin-Releasing Hormone - agonists | Prostatic Neoplasms - drug therapy | Hematologic Diseases - chemically induced | Somatostatin - analogs & derivatives | Dexamethasone - administration & dosage | Etoposide - adverse effects | Prostatic Neoplasms - surgery | Antineoplastic Agents, Hormonal - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Triptorelin Pamoate - adverse effects | Combined Modality Therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Prostatic Neoplasms - mortality | Orchiectomy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Diabetes Mellitus - chemically induced | Aged | Estramustine - adverse effects | Peptides, Cyclic - adverse effects | Gastrointestinal Diseases - chemically induced | Adenocarcinoma - mortality | Adenocarcinoma - surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
42. Full Text Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
by Matsui, William and Wang, Qiuju and Barber, James P and Brennan, Sarah and Smith, B. Douglas and Borrello, Ivan and McNiece, Ian and Lin, Lan and Ambinder, Richard F and Peacock, Craig and Watkins, D. Neil and Huff, Carol Ann and Jones, Richard J
Cancer Research, ISSN 0008-5472, 01/2008, Volume 68, Issue 1, pp. 190 - 197
Many agents are active in multiple myeloma, but the majority of patients relapse. This clinical pattern suggests most cancer cells are eliminated, but cells... 
BREAST-CANCER | CIRCULATING B-CELLS | ONCOLOGY | BONE-MARROW | LEUKEMIC B | IN-VIVO | PERIPHERAL-BLOOD | TUMOR-CELLS | MICE | IDENTIFICATION | PLASMA-CELLS | Cyclophosphamide - analogs & derivatives | Clone Cells - drug effects | Neoplastic Stem Cells - drug effects | Humans | Drug Resistance, Neoplasm | Thalidomide - pharmacology | Plasma Cells - pathology | Plasma Cells - drug effects | Thalidomide - analogs & derivatives | Dexamethasone - pharmacology | Neoplastic Stem Cells - pathology | Antineoplastic Agents - pharmacology | Antigens, CD20 - analysis | B-Lymphocytes - pathology | Tumor Stem Cell Assay | Bortezomib | Mice, Inbred Strains | Syndecan-1 - analysis | Multiple Myeloma - pathology | Animals | Clone Cells - pathology | Cyclophosphamide - pharmacology | Mice | Tumor Necrosis Factor Receptor Superfamily, Member 7 - analysis | Pyrazines - pharmacology | Boronic Acids - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
43. Full Text In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
by Chauhan, Dharminder and Tian, Ze and Zhou, Bin and Kuhn, Deborah and Orlowski, Robert and Raje, Noopur and Richardson, Paul and Anderson, Kenneth C
Clinical Cancer Research, ISSN 1078-0432, 08/2011, Volume 17, Issue 16, pp. 5311 - 5321
Purpose: The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel... 
THERAPY | CANCER CELLS | ONCOLOGY | INDUCED APOPTOSIS | GROWTH | DRUG-RESISTANCE | BORTEZOMIB | COMBINATION | NF-KAPPA-B | GENETIC ABNORMALITIES | P53 | Glycine - analogs & derivatives | Caspase 9 - metabolism | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Caspase 8 - metabolism | Biological Availability | NF-kappa B - metabolism | Thalidomide - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Glycine - pharmacokinetics | Boron Compounds - pharmacology | Cell Survival - drug effects | Bortezomib | Administration, Oral | Boron Compounds - pharmacokinetics | Enzyme Activation - drug effects | Mice, SCID | Multiple Myeloma - metabolism | Blotting, Western | Drug Synergism | Xenograft Model Antitumor Assays | Multiple Myeloma - pathology | Animals | Glycine - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Proteasome Endopeptidase Complex - metabolism | Proteasome Inhibitors | Pyrazines - pharmacology | Boronic Acids - pharmacology | Novel therapeutics | Myeloma | Proteasome inhibitor | Apoptosis | Proteasome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
44. Full Text A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
by Richardson, Paul G and Blood, Emily and Mitsiades, Constantine S and Jagannath, Sundar and Zeldenrust, Steven R and Alsina, Melissa and Schlossman, Robert L and Rajkumar, S. Vincent and Desikan, K. Raman and Hideshima, Teru and Munshi, Nikhil C and Kelly-Colson, Kathleen and Doss, Deborah and McKenney, Mary L and Gorelik, Svetlana and Warren, Diane and Freeman, Andrea and Rich, Rebecca and Wu, Anfang and Olesnyckyj, Marta and Wride, Kenton and Dalton, William S and Zeldis, Jerome and Knight, Robert and Weller, Edie and Anderson, Kenneth C
Blood, ISSN 0006-4971, 11/2006, Volume 108, Issue 10, pp. 3458 - 3464
This multicenter, open-label, randomized phase 2 study evaluated 2 dose regimens of lenalidomide for relapsed, refractory myeloma. Seventy patients were... 
CC-5013 | THALIDOMIDE PLUS DEXAMETHASONE | ANALOGS | COMBINATION THERAPY | NEWLY-DIAGNOSED MYELOMA | OPEN-LABEL | HIGH-DOSE CHEMOTHERAPY | DRUG-RESISTANCE | BORTEZOMIB | HEMATOLOGY | CELL | Recurrence | Salvage Therapy - adverse effects | Peripheral Nervous System Diseases - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Venous Thrombosis - chemically induced | Multiple Myeloma - complications | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Survival Rate | Thalidomide - administration & dosage | Thalidomide - toxicity | Thalidomide - pharmacokinetics | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Remission Induction - methods | Aged | Salvage Therapy - methods | Neoplasia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
45. Full Text Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: Safety and efficacy
by Baz, R and Walker, E and Karam, M.A and Choueiri, T.K and Jawde, R.A and Bruening, K and Reed, J and Faiman, B and Ellis, Y and Brand, C and Srkalovic, G and Andresen, S and Knight, R and Zeldis, J and Hussein, M.A
Annals of Oncology, ISSN 0923-7534, 12/2006, Volume 17, Issue 12, pp. 1766 - 1771
Background: Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma. We conducted a phase I/II trial of the combination of... 
Refractory | Doxil | Lenalidomide | Reduced dose dexamethasone | Multiple Myeloma | refractory | multiple myeloma | DEXAMETHASONE | ONCOLOGY-GROUP | ANALOGS | PHASE-2 | THALIDOMIDE | TNF-ALPHA PRODUCTION | THROMBOTIC COMPLICATIONS | ONCOLOGY | VINCRISTINE | UNDETERMINED SIGNIFICANCE | MONOCLONAL GAMMOPATHY | lenalidomide | reduced dose dexamethasone | Doxorubicin - therapeutic use | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Thalidomide - administration & dosage | Polyethylene Glycols - therapeutic use | Polyethylene Glycols - administration & dosage | Thalidomide - analogs & derivatives | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Doxorubicin - analogs & derivatives | Female | Aged | Thalidomide - therapeutic use | Doxorubicin - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
46. Full Text Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
by Streetly, Matthew J and Gyertson, Kylie and Daniel, Yvonne and Zeldis, Jerome B and Kazmi, Majid and Schey, Stephen A
British Journal of Haematology, ISSN 0007-1048, 04/2008, Volume 141, Issue 1, pp. 41 - 51
Summary We previously reported that daily dose pomalidomide (CC-4047), a thalidomide analogue, has excellent anti-myeloma activity but is associated with... 
immunomodulation | myeloma | CC-4047 | pomalidomide | thalidomide analogue | CC‐4047 | Pomalidomide | Thalidomide analogue | Myeloma | Immunomodulation | CELLS | REFRACTORY MULTIPLE-MYELOMA | ANGIOGENESIS | VENOUS THROMBOSIS | PHASE-II | DRUG-RESISTANCE | POTENT INHIBITORS | THERAPY | THALIDOMIDE ANALOGS | TNF-ALPHA | HEMATOLOGY | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Neutropenia - chemically induced | Thalidomide - adverse effects | Drug Administration Schedule | Lymphocyte Subsets - drug effects | Immunologic Factors - administration & dosage | Treatment Outcome | Thalidomide - administration & dosage | Blood Cell Count | Dexamethasone - therapeutic use | Maximum Tolerated Dose | Survival Analysis | Aged | Immunologic Factors - adverse effects | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
47. Full Text Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
by Stewart, A. Keith and Rajkumar, S. Vincent and Dimopoulos, Meletios A and Masszi, Tamás and Špička, Ivan and Oriol, Albert and Hájek, Roman and Rosiñol, Laura and Siegel, David S and Mihaylov, Georgi G and Goranova-Marinova, Vesselina and Rajnics, Péter and Suvorov, Aleksandr and Niesvizky, Ruben and Jakubowiak, Andrzej J and San-Miguel, Jesus F and Ludwig, Heinz and Wang, Michael and Maisnar, Vladimír and Minarik, Jiri and Bensinger, William I and Mateos, Maria-Victoria and Ben-Yehuda, Dina and Kukreti, Vishal and Zojwalla, Naseem and Tonda, Margaret E and Yang, Xinqun and Xing, Biao and Moreau, Philippe and Palumbo, Antonio and ASPIRE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
In this study, the addition of carfilzomib to lenalidomide and dexamethasone improved response rates and overall survival among patients with relapsed multiple... 
SINGLE-AGENT CARFILZOMIB | SURVIVAL | MEDICINE, GENERAL & INTERNAL | PLUS DEXAMETHASONE | RANDOMIZED PHASE-III | BORTEZOMIB | STEM-CELL TRANSPLANTATION | COMBINATION | LOW-DOSE DEXAMETHASONE | PX-171-006 | ESCALATION | Thalidomide - adverse effects | Recurrence | Dexamethasone - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Thalidomide - administration & dosage | Oligopeptides - adverse effects | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Oligopeptides - administration & dosage | Treatment outcome | Dexamethasone | Analysis | Multiple myeloma | Carfilzomib | Dosage and administration | Drug therapy | Risk factors | Quality of life | Chemotherapy | Clinical trials | Survival | Patients | Proteasome inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
48. Full Text Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
by Paul G. Richardson and Edie Weller and Sundar Jagannath and David E. Avigan and Melissa Alsina and Robert L. Schlossman and Amitabha Mazumder and Nikhil C. Munshi and Irene M. Ghobrial and Deborah Doss and Diane L. Warren and Laura E. Lunde and Mary McKenney and Carol Delaney and Constantine S. Mitsiades and Teru Hideshima and William Dalton and Robert Knight and Dixie-Lee Esseltine and Kenneth C. Anderson
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 34, pp. 5713 - 5719
Purpose Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM... 
CELLS | DEXAMETHASONE | PREDNISONE | THERAPY | ONCOLOGY | ANALOGS | REFRACTORY MYELOMA | OVERCOMES DRUG-RESISTANCE | THALIDOMIDE | COMBINATION | MELPHALAN | Recurrence | Glucocorticoids - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Drug Resistance, Neoplasm | Male | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Boronic Acids - administration & dosage | Glucocorticoids - adverse effects | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Thalidomide - administration & dosage | Maximum Tolerated Dose | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Aged | Index Medicus | Original Reports | Hema21
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
49. Full Text Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
by Dimopoulos, Meletios A and Oriol, Albert and Nahi, Hareth and San-Miguel, Jesus and Bahlis, Nizar J and Usmani, Saad Z and Rabin, Neil and Orlowski, Robert Z and Komarnicki, Mieczyslaw and Suzuki, Kenshi and Plesner, Torben and Yoon, Sung-Soo and Ben Yehuda, Dina and Richardson, Paul G and Goldschmidt, Hartmut and Reece, Donna and Lisby, Steen and Khokhar, Nushmia Z and O’Rourke, Lisa and Chiu, Christopher and Qin, Xiang and Guckert, Mary and Ahmadi, Tahamtan and Moreau, Philippe and POLLUX Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2016, Volume 375, Issue 14, pp. 1319 - 1331
The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide... 
SURVIVAL | CRITERIA | MEDICINE, GENERAL & INTERNAL | MONOTHERAPY | ELOTUZUMAB | ANTIBODY DARATUMUMAB | CD38 | OPEN-LABEL | INTERFERENCE | Recurrence | Dexamethasone - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Thalidomide - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Care and treatment | Usage | Dexamethasone | Diagnosis | Multiple myeloma | Thrombocytopenia | Minimal residual disease | Leukocytes | Health risk assessment | Drug therapy | Patients | Neutropenia | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
50. Full Text Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
by Dimopoulos, M.A and Leleu, X and Palumbo, A and Moreau, P and Delforge, M and Cavo, M and Ludwig, H and Morgan, G.J and Davies, F.E and Sonneveld, P and Schey, S.A and Zweegman, S and Hansson, M and Weisel, K and Mateos, M.V and Facon, T and Miguel, J.F.S and Division of Hematology and Transfusion Medicine and Lund University and BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation and Lunds universitet and Avdelningen för hematologi och transfusionsmedicin
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 8, pp. 1573 - 1585
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based... 
TUMOR-NECROSIS-FACTOR | NATURAL-KILLER-CELLS | VENOUS THROMBOEMBOLISM | ONCOLOGY | GROWTH-FACTORS | LENALIDOMIDE PLUS DEXAMETHASONE | PERIPHERAL NEUROPATHY | THALIDOMIDE ANALOGS | BORTEZOMIB | HEMATOLOGY | HIGH-DOSE DEXAMETHASONE | AMERICAN SOCIETY | Thalidomide - adverse effects | Peripheral Nervous System Diseases - chemically induced | Dexamethasone - administration & dosage | Age Factors | Drug Administration Schedule | Multiple Myeloma - psychology | Humans | Clinical Trials as Topic | Thalidomide - administration & dosage | Thalidomide - pharmacology | Infection - chemically induced | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Venous Thromboembolism - chemically induced | Quality of Life | Thalidomide - therapeutic use | Neutropenia - chemically induced | Multiple Myeloma - genetics | Immunologic Factors - therapeutic use | Dose-response relationship (Biochemistry) | Pharmacology, Experimental | Oncology, Experimental | Multiple myeloma | Research | Drug therapy | Cancer | Index Medicus | Review | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
51. Full Text Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T‐cell lymphoma: report of a case with long‐term follow‐up
by Fabbri, Alberto and Cencini, Emanuele and Pietrini, Alice and Gozzetti, Alessandro and Defina, Marzia and Fontanelli, Giulia and Mazzei, Maria Antonietta and Volterrani, Luca and Bocchia, Monica
Hematological Oncology, ISSN 0278-0232, 12/2013, Volume 31, Issue 4, pp. 213 - 217
Angioimmunoblastic T‐cell lymphoma (AITL) is characterized by an aggressive clinical course and unfavourable prognosis. Refractory AITL patients have very few... 
chemorefractory | lenalidomide | AITL | salvage treatment | Chemorefractory | Salvage treatment | Lenalidomide | PHASE-II TRIAL | ACTIVATION | ONCOLOGY | THALIDOMIDE ANALOGS | HEMATOLOGY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Clinical Trials as Topic - statistics & numerical data | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Drugs, Investigational - therapeutic use | Drug Resistance, Neoplasm | Male | Vinblastine - administration & dosage | Thalidomide - analogs & derivatives | Organoplatinum Compounds - administration & dosage | Vinblastine - analogs & derivatives | Doxorubicin - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Doxorubicin - administration & dosage | Lymphoma, T-Cell, Peripheral - drug therapy | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Combined Modality Therapy | Lymphoma, T-Cell, Peripheral - radiotherapy | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Thalidomide - therapeutic use | Deoxycytidine - analogs & derivatives | Immunologic Factors - therapeutic use | T cells | Radiotherapy | Lymphomas
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
52. Full Text Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
by Quarta, Carmelo and Clemmensen, Christoffer and Zhu, Zhimeng and Yang, Bin and Joseph, Sini S and Lutter, Dominik and Yi, Chun-Xia and Graf, Elisabeth and García-Cáceres, Cristina and Legutko, Beata and Fischer, Katrin and Brommage, Robert and Zizzari, Philippe and Franklin, Bernardo S and Krueger, Martin and Koch, Marco and Vettorazzi, Sabine and Li, Pengyun and Hofmann, Susanna M and Bakhti, Mostafa and Bastidas-Ponce, Aimée and Lickert, Heiko and Strom, Tim M and Gailus-Durner, Valerie and Bechmann, Ingo and Perez-Tilve, Diego and Tuckermann, Jan and Hrabě de Angelis, Martin and Sandoval, Darleen and Cota, Daniela and Latz, Eicke and Seeley, Randy J and Müller, Timo D and DiMarchi, Richard D and Finan, Brian and Tschöp, Matthias H
Cell Metabolism, ISSN 1550-4131, 10/2017, Volume 26, Issue 4, pp. 620 - 632.e6
Chronic inflammation has been proposed to contribute to the pathogenesis of diet-induced obesity. However, scarce therapeutic options are available to treat... 
dexamethasone | hypothalamic inflammation | conjugate | GLP-1 | type 2 diabetes | co-agonist | anti-inflammatory | drug delivery | obesity | LEPTIN | ACTIVATION | LIRAGLUTIDE | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | HYPOTHALAMIC INFLAMMATION | MICE | MECHANISMS | STRESS | BETA/NF-KAPPA-B | GLUCAGON | CELL BIOLOGY | Glucocorticoids - therapeutic use | Obesity - drug therapy | Humans | Body Weight - drug effects | Male | Dexamethasone - analogs & derivatives | Inflammation - complications | Inflammation - metabolism | Inflammation - drug therapy | HEK293 Cells | Hypothalamus - drug effects | Incretins - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Mice, Inbred C57BL | Obesity - metabolism | Dexamethasone - therapeutic use | Animals | Hypothalamus - metabolism | Glucocorticoids - chemistry | Glucose - metabolism | Mice, Obese | Mice | Incretins - therapeutic use | Energy Metabolism - drug effects | Glucagon-Like Peptide 1 - therapeutic use | Obesity | Dexamethasone | Glucagon | Health aspects | Body weight | Steroids | Corticosteroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights